(Q45710707)

English

Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.

scientific article published in August 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

atherosclerosis

1 reference

based on heuristic

inferred from title

platelet aggregation

1 reference

based on heuristic

inferred from title

Robert F. Storey

1

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Håkan Emanuelsson

6

object named as

Håkan Emanuelsson

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Christopher P Cannon

7

object named as

Christopher P Cannon

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

author name string

S Melissa Thornton

2

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Rachael Lawrance

3

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Steen Husted

4

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Mark Wickens

5

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Stan Heptinstall

8

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Martin Armstrong

9

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

publication date

1 August 2009

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

341-348

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Biology and pharmacology of the platelet P2Y12 receptor

1 reference

https://api.crossref.org/works/10.1080%2F09537100903075324

21 January 2018

Clopidogrel: a review of its mechanism of action

1 reference

https://api.crossref.org/works/10.1080%2F09537100903075324

21 January 2018

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

1 reference

https://api.crossref.org/works/10.1080%2F09537100903075324

21 January 2018

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1080%2F09537100903075324

21 January 2018

Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation

1 reference

https://api.crossref.org/works/10.1080%2F09537100903075324

21 January 2018

Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study

1 reference

https://api.crossref.org/works/10.1080%2F09537100903075324

21 January 2018

Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.

1 reference

https://api.crossref.org/works/10.1080%2F09537100903075324

21 January 2018

Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1080%2F09537100903075324

21 January 2018

P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose

1 reference

https://api.crossref.org/works/10.1080%2F09537100903075324

21 January 2018

Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.

1 reference

https://api.crossref.org/works/10.1080%2F09537100903075324

21 January 2018

P2Y1 gene polymorphism and ADP-induced platelet response

1 reference

https://api.crossref.org/works/10.1080%2F09537100903075324

21 January 2018

Pharmacogenetics of aspirin resistance: a comprehensive systematic review

1 reference

https://api.crossref.org/works/10.1080%2F09537100903075324

21 January 2018

PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation

1 reference

https://api.crossref.org/works/10.1080%2F09537100903075324

21 January 2018

Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination

1 reference

https://api.crossref.org/works/10.1080%2F09537100903075324

21 January 2018

Preclinical and clinical studies with selective reversible direct P2Y12 antagonists

1 reference

https://api.crossref.org/works/10.1080%2F09537100903075324

21 January 2018

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

1 reference

https://api.crossref.org/works/10.1080%2F09537100903075324

21 January 2018

Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE

1 reference

https://api.crossref.org/works/10.1080%2F09537100903075324

21 January 2018

Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1080%2F09537100903075324

21 January 2018

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

1 reference

https://api.crossref.org/works/10.1080%2F09537100903075324

21 January 2018

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

1 reference

https://api.crossref.org/works/10.1080%2F09537100903075324

21 January 2018

Cytochrome p-450 polymorphisms and response to clopidogrel

1 reference

https://api.crossref.org/works/10.1080%2F09537100903075324

21 January 2018

Genetic determinants of response to clopidogrel and cardiovascular events

1 reference

https://api.crossref.org/works/10.1080%2F09537100903075324

21 January 2018

Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel.

1 reference

https://api.crossref.org/works/10.1080%2F09537100903075324

21 January 2018

Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) tria

1 reference

https://api.crossref.org/works/10.1080%2F09537100903075324

21 January 2018

Identifiers

10.1080/09537100903075324

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45710707&oldid=1810825376"